Evaluating evidence for a neuropsychological toolkit to predict cognitive decline in PD: A systematic review
- PMID: 40464273
- DOI: 10.1080/13854046.2025.2511966
Evaluating evidence for a neuropsychological toolkit to predict cognitive decline in PD: A systematic review
Abstract
Objectives: Neuropsychological measures used to assess cognition in Parkinson's disease (PD) vary greatly across clinical and research settings. We conducted a systematic review to evaluate the literature pertaining to neuropsychological tools predictive of cognitive decline in PD, with a view to developing an evidence-based harmonized toolkit. Method: Following PRISMA guidelines, systematic literature searches for neuropsychological predictors of longitudinal cognitive decline in PD were performed for articles published up to August 2024 in PubMed, SCOPUS, Medline, PyscINFO and CINAHL databases. Quality was assessed using the Newcastle-Ottawa scale for individual studies and the GRADE system for each cognitive outcome. Results: Thirty-one relevant articles met inclusion criteria, with low to moderate risk of bias. Category fluency, Symbol Digit Modalities Test, Trail-making Test part A, Stroop word or color, immediate verbal memory, and Montreal Cognitive Assessment produced the highest grade of evidence (moderate), strongly supporting their predictive utility in PD. Stroop word-color, Letter Number Sequencing, pentagon copying, Trail-making Test part B, and delayed verbal and visual memory produced low quality evidence supporting their predictive utility in PD. Digit span forward and backward measures produced very low quality evidence, with consistent evidence against their predictive utility. Twelve additional measures produced very low quality of evidence due to insufficient studies or mixed results. Conclusions: The evidence base for key neuropsychological measures sensitive to cognitive decline in PD was evaluated in this systematic review. The findings will inform evidence-based tool selection for cognitive evaluations in PD and a PD-specific harmonized cognitive toolkit.
Keywords: Cognitive impairment; Parkinson’s disease; dementia.
Similar articles
-
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article.
-
Time-course of decline in different cognitive domains in Parkinson's disease: a retrospective study.J Neural Transm (Vienna). 2022 Sep;129(9):1179-1187. doi: 10.1007/s00702-021-02441-w. Epub 2021 Nov 24. J Neural Transm (Vienna). 2022. PMID: 34817687
-
Cognitive training interventions for dementia and mild cognitive impairment in Parkinson's disease.Cochrane Database Syst Rev. 2020 Feb 26;2(2):CD011961. doi: 10.1002/14651858.CD011961.pub2. Cochrane Database Syst Rev. 2020. PMID: 32101639 Free PMC article.
-
Diagnostic and screening power of neuropsychological testing in detecting mild cognitive impairment in Parkinson's disease.J Neural Transm (Vienna). 2013 Apr;120(4):627-33. doi: 10.1007/s00702-013-1004-2. Epub 2013 Mar 13. J Neural Transm (Vienna). 2013. PMID: 23483334
-
Screening for Cognitive Impairment in Older Adults: An Evidence Update for the U.S. Preventive Services Task Force [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Nov. Report No.: 14-05198-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Nov. Report No.: 14-05198-EF-1. PMID: 24354019 Free Books & Documents. Review.
Cited by
-
Diagnosis, evaluation, and management of cognitive disorders in Parkinson's disease: Consensus recommendations from a modified Delphi process.Alzheimers Dement (Amst). 2025 Jul 24;17(3):e70152. doi: 10.1002/dad2.70152. eCollection 2025 Jul-Sep. Alzheimers Dement (Amst). 2025. PMID: 40708679 Free PMC article.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous